Headquartered in Cincinnati, OH Fiscal year ends December NYSE: CHE chemed.com
Chemed Corporation operates two distinct businesses. Through its VITAS Healthcare Corporation subsidiary, Chemed is one of the largest providers of end-of-life hospice care in the United States, delivering daily hospice services to patients with severe, life-limiting illnesses across homecare, inpatient, and continuous care settings. VITAS operates 60 hospice programs spanning 14 large (greater than 450 ADC), 25 medium (200–450 ADC), and 21 small (less than 200 ADC) programs with 33 Medicare provider numbers. Through its Roto-Rooter subsidiary, Chemed is the largest provider of commercial and residential plumbing, drain cleaning, excavation, and water restoration services in the United States. Roto-Rooter operates through company-owned branches, independent contractors, and franchisees in the U.S. and Canada, with licensed master franchisees in Indonesia, Singapore, and the Philippines. Updated
Medicare Cap billing limitations at VITAS shrank to $828,000 from $6.1 million a year ago, powering a beat on both lines. Management now sees full-year adjusted EPS at or slightly above the high end of prior guidance.
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed…
It should come as no surprise to see insider selling at current market levels, and we expect the pace to continue through the rest of the summer and into the fall.
Chemed Corp. (NYSE: CHE) is a very strange company. Imagine owning the Roto Rooter drain cleaning and plumbing company AND owning a for-profit hospice provider. Now a Department of Justice suit against…
Jon C. Ogg ACL started as Buy at Jefferies.AMGN started as Mkt Perform at Rodman & Renshaw.B started as Outperform at CIBC.CBB started as Buy at UBS.CHE started as Buy at Jefferies.CTL raised to Neutral…
Chemed Corporation operates two distinct businesses.
24/7 Wall St.'s 12-month price target for CHE is $623.22, rated Buy. The Wall Street consensus target is $571.60. CHE price prediction →
